Lilly and Merck extend immuno-oncology collaboration
November 20, 2015Medical Communications, Research and Development Eli Lilly, Merck
Eli Lilly and Merck have announced the extension of their existing collaboration to evaluate the safety and efficacy of the …
Bayer awaits FDA decision on new contraceptive
November 20, 2015Medical Communications, Research and Development
Bayer has submitted a new drug application (NDA) to the FDA, seeking approval for LCS-16, an investigational hormonal intrauterine device …
PMCPA rules on two Bayer conduct breach allegations
November 20, 2015Medical Communications, Sales and Marketing
The pharma industry regulator in the UK, the PMCPA, has ruled on two alleged breaches of the ABPI code of …
Top five pharma controversies of 2015 (so far)
November 20, 2015Medical Communications, Sales and Marketing AstraZeneca, Martin Shkreli, Philidore, Takeda, Turing Pharmaceutical, Valeant, Warner Chilcott, controversies, fraud, reputation, tax avoidance, turing
5. AstraZeneca forced to deny tax avoidance allegations
New partner drives Simon-Kucher’s Life Sciences growth in the UK
November 19, 2015Medical Communications
The global strategy and marketing consultancy Simon-Kucher & Partners has appointed eleven new partners for 2016, with eight of them …
American Medical Association calls for ban on drug commercials
November 19, 2015Medical Communications, Sales and Marketing
The American Medical Association (AMA) has called for a ban on the promotion of prescription products; action which it believes …
NHS England and NICE announce plans for new Cancer Drugs Fund
November 19, 2015Medical Communications, Research and Development Cancer Drugs Fund, NHS England, NICE
A 12-week consultation on draft proposals for a revamped Cancer Drugs Fund (CDF) has been launched by NHS England and NICE, …
Physicians Interactive becomes Aptus Health, offering a global digital health engagement solution
November 19, 2015Medical Communications
Physicians Interactive has announced that it has become Aptus Health, reflecting its mission of advancing health engagement and its role …
NICE decision restricts Bayer’s Xofigo to select prostate cancer patients
November 19, 2015Research and Development, Sales and Marketing Bayer, NICE, prostate cancer
NICE has issued its Final Appraisal Determination (FAD) recommending Bayer’s Xofigo (radium-223 dichloride) for use on the NHS in England …
FDA grants Merck and Pfizer priority review for PD-L1 cell treatment
November 19, 2015The FDA has granted Merck and Pfizer’s avelumab Breakthrough Therapy Designation for the treatment of patients with metastatic merkel cell …
Merck criticises NICE ‘no’ to personalised bowel cancer drugs
November 19, 2015Research and Development
NICE has issued preliminary not recommending two specific personalised treatments used in combination with chemotherapy for previously untreated metastatic colorectal …
Merck KGaA completes $17bn Sigma-Aldrich acquisition
November 18, 2015Manufacturing and Production, Sales and Marketing M&A Sigma Aldridge, Merck, acquisitions, mergers
Merck KGaA has announced the completion of its $17 billion acquisition of Sigma-Aldrich, having cleared the final regulatory hurdle and …
Obama FDA commissioner nominee Califf defends big pharma ties
November 18, 2015Sales and Marketing Bernie Sanders, FDA, FDA commissioner, Robert Califf
President Obama’s nominee to head the FDA was forced to defend his history of ties to the pharma industry as …
Raising Awareness: World COPD Day
November 18, 2015Medical Communications COPD, COPD disease, COPD exacerbation, Synergy Vision, disease awareness, medical communications
World COPD Day 18th November 2015
NICE rejects Amgen’s Repatha in draft guidance
November 18, 2015Research and Development, Sales and Marketing Amgen, NICE, Repatha, evolocumab, high cholesterol
NICE has published draft guidance rejecting Amgen’s Repatha as a treatment for people with high cholesterol.
Challenges in oncology R&D
November 18, 2015Manufacturing and Production, Research and Development Dixie-Lee Esseltine, Takeda, Takeda oncology, Velcade, multiple myeloma, oncology
Pharmafile put questions on the challenges pharma companies face when working in oncology R&D to Dixie-Lee Esseltine, vice president of …
FDA accepts regulatory submission for Novartis biosimilar
November 18, 2015Research and Development, Sales and Marketing Neulasta, Novartis, Sandoz, biosimilar, pegfilgrastim
Novartis’ generics unit Sandoz has announced it has had its Biologics License Application (BLA) for a proposed biosimilar to Amgen’s …
Global drug spending will rise 30% by 2020, to $1.4 trillion
November 18, 2015Research and Development IMS Health, OTC, drug spending, emerging markets, generics, prescribing
Global spending on drugs will increase 30% to $1.4 trillion by 2020, as more patients get access to treatments and …
Scientists make possible pancreatic cancer discovery
November 18, 2015Research and Development Pancreatic cancer
Cancer researchers say they have discovered a potential new method of treatment for pancreatic cancer that could improve survival rates. …
UCB appoints Steve Turley as MD for Britain and Ireland
November 18, 2015Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UCB
Steve Turley has joined UCB as the company’s managing director for the British and Irish isles, moving from Lundbeck. He …
Latest content
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer
